Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
AstraZeneca
Dow
Boehringer Ingelheim
Johnson and Johnson

Last Updated: May 17, 2022

FABIOR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Fabior, and when can generic versions of Fabior launch?

Fabior is a drug marketed by Mayne Pharma and is included in one NDA. There are three patents protecting this drug.

This drug has twenty-four patent family members in eighteen countries.

The generic ingredient in FABIOR is tazarotene. There are eight drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the tazarotene profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Fabior

A generic version of FABIOR was approved as tazarotene by TARO PHARMS on April 3rd, 2017.

  Try it Free

Drug patent expirations by year for FABIOR
Drug Prices for FABIOR

See drug prices for FABIOR

Recent Clinical Trials for FABIOR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Actavis Inc.Phase 3

See all FABIOR clinical trials

Pharmacology for FABIOR
Drug ClassRetinoid

US Patents and Regulatory Information for FABIOR

FABIOR is protected by three US patents.

Patents protecting FABIOR

Topical foam composition
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OF AGE OR OLDER

Topical foam composition
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OF AGE OR OLDER

Topical foam composition
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mayne Pharma FABIOR tazarotene AEROSOL, FOAM;TOPICAL 202428-001 May 11, 2012 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Mayne Pharma FABIOR tazarotene AEROSOL, FOAM;TOPICAL 202428-001 May 11, 2012 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Mayne Pharma FABIOR tazarotene AEROSOL, FOAM;TOPICAL 202428-001 May 11, 2012 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for FABIOR

See the table below for patents covering FABIOR around the world.

Country Patent Number Title Estimated Expiration
South Korea 20110138353 TOPICAL FOAM COMPOSITION See Plans and Pricing
South Korea 101725196 See Plans and Pricing
Chile 2011002053 Composicion farmaceutica de espuma en aerosol en emulsion de aceite en agua que comprende un agente farmaceuticamente activo, agua, aceite, disolvente organico, componente tensoactivo, y propulsor; procedimiento de preparacion; uso para tratar enfermedades, o afecciones de la piel. See Plans and Pricing
Brazil PI1008037 composição de espuma tópica See Plans and Pricing
Mexico 2011008912 COMPOSICION DE ESPUMA TOPICA. (TOPICAL FOAM COMPOSITION.) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for FABIOR

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0284288 12/1998 Austria See Plans and Pricing PRODUCT NAME: TAZAROTENE; NAT. REGISTRATION NO/DATE: 1-22102, 1-22103 19970918; FIRST REGISTRATION: DE 37393.00.00, 37393.01.00 19961203
0031058 98C0008 Belgium See Plans and Pricing PRODUCT NAME: TAZAROTENE; NAT. REGISTRATION NO/DATE: NL22604 19970922; FIRST REGISTRATION: DE - 37393.00.00 19961203
0284288 SPC/GB98/002 United Kingdom See Plans and Pricing PRODUCT NAME: TAZAROTENE : ETHYL 6-(2-(4,4-DIMETHYLTHIOCHROMAN-6-YL) ETHYNYL) NICOTINOATE; REGISTERED: DE 37393.00.00 19961203; DE 37393.01.00 19961203; UK 00426/0097 19970730; UK 00426/0096 19970730
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Merck
Medtronic
Moodys
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.